



Grant Number: 4U01CA033193-32

Principal Investigator(s):
Kurt Straif

Project Title: Evaluation of Carcinogenic Risks to Humans

INTERNATIONAL AGENCY-RES CANCER
150 COURS ALBERT THOMAS
F-69372 LYON CEDEX 08, FRANCE,
FRANCE

Award e-mailed to: igo@iarc.fr

Budget Period: 09/01/2013 – 08/31/2014
Project Period: 09/01/1985 – 08/31/2015

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$780,856 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U01CA033193. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with 42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August 24, 2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with the 1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Joy Kearse
Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 4U01CA033193-32

Award Calculation (U.S. Dollars)

Salaries and Wages	\$369,270
Fringe Benefits	\$123,092
Consultant Services	\$39,566
Travel Costs	\$2,134
Other Costs	\$140,860

Federal Direct Costs	\$674,922
Federal F&A Costs	\$108,662
Approved Budget	\$783,584
Federal Share	\$783,584
Less Unobligated Balance	\$2,728
TOTAL FEDERAL AWARD AMOUNT	\$780,856

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$780,856

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
32	\$780,856	\$780,856
33	(b)(5)	

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Number: 93.393
 EIN: 1900210016A1
 Document Number: UCA033193H
 Fiscal Year: 2013

IC	CAN	2013	2014
CA	8479565	\$780,856	(b)(5)

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A3CE / OC: 414P / Released: KEARSEJ 09/09/2013
 Award Processed: 09/10/2013 12:06:23 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 4U01CA033193-32

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 4U01CA033193-32

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Treatment of Program Income:
Additional Costs

SECTION IV – CA Special Terms and Conditions – 4U01CA033193-32

REQUIREMENT: This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award below, which are hereby incorporated by reference as special terms and conditions of this award.

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

Collaborative Terms of Award

Nature of Collaboration with NCI Staff

NCI has certain responsibilities in terms of this cooperative agreement which involve assistance, information support, and scientific collaboration.

1. Scientific Resource

Since the monographs on each chemical which appear in the columns published by IARC are fundamentally an international information resource and data bank on carcinogenesis and evaluation of qualitative risk of chemicals to human, NCI, in an assistance and cooperative role, provides information and data which assist IARC staff in the preparation of certain sections of the final monograph (Sections 1.1 to 2.3). Sections 3.1 to 4.3 are developed by the Working Groups which consist of international scientists who review all these documents at the time of the meetings (3 per year) in Lyon, France. The National Cancer Institute, through arrangements with a contractor will provide such assistance.

2. Planning for Meetings of the Working Group

The IARC project is one of international support with NCI being the USA supporter for the monograph and the Information Bulletins on the Survey of Chemicals Being Tested for Carcinogenicity. This bulletin is a listing of chemicals being tested in laboratories throughout the world. Under the Cooperative Agreement, NCI:

a. Makes suggestions to IARC on types of chemicals that should be evaluated at the three planned working group meetings per held in Lyon, France.

b. Makes suggestions and gives assistance to IARC as to USA resource people who should attend and participate in Working Group meetings. Personnel from regulatory agencies and trade associations should attend as observers.

3. Program Involvement in Relation to Input from NCI

Under the section on scientific resources, reference was made to NCI input as to data on production, occurrence, analysis, and use of chemicals. NCI, also provides information relevant to carcinogenicity on chemicals tested in U.S. laboratories. These data are then incorporated in the Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity.

In discussing certain phases of work that involve assistance and collaboration on the part of NCI with IARC, reference was made to the essentiality of effective liaison and support. Participation by the NCI Program Director in the working group meetings in Lyon, France could be either as an observer or as a representative of NCI or as a full member of the working group in his personal capacity as a scientist.

4. Reporting Requirements

NCI wishes to continue a semi-annual reporting requirement with scheduling or due dates for reports worked out by mutual agreement between NCI staff and the IARC principal investigators. The volumes of monographs, supplements and survey bulletins are actually exhibits of achievements and accomplishment. Consequently, the semi-annual reports should dwell on planning, participation, selection of chemicals, problems of interfacing and cooperation and logistical matters. In addition, an annual report to be included in the required continuation applications should reflect that the project continues to conform to the purposes, objectives and conditions of the award and has substantial programmatic involvement by NCI with the performer of the project.

5. Publication and Distribution

One of the significant features of the IARC project in development of this international authoritative reference source is the publication and distribution, on a world-wide basis, of these volumes, including the supplements to the volumes listing Chemicals and Industrial Processes Associated with Cancer in Humans, as well as the Survey Bulletins.

The National Cancer Institute will receive approximately 400 copies of each volume published. The NCI distributes these copies to NCI staff, representatives of other agencies interested in environmental and occupational carcinogenesis, selected university scientist engaged in carcinogenesis research, public health organizations and medical libraries. Therefore, many organizations and scientists in the USA and abroad benefit from this program, which is partially supported by the National Cancer Institute.

The following administrative terms also apply:

REQUIREMENT: If a renewal application is submitted for this project, the requested budget is subject to the direct cost cap calculated in accordance with the National Cancer Institute's (NCI) policy, "Policy for Allowable Requested Budget Levels of Renewal (Type 2) R01, U01 and P01 Applications." This policy was announced in the NIH Guide for Grants and Contracts on August 15, 2008 and can be found at: <http://grants.nih.gov/grants/guide/notice-files/NOT-CA-08-026.html>

INFORMATION: The policies and procedures announced in Guide Notice NOT-OD-12-139, <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-139.html> apply to this award.

INFORMATION: This award includes funds for twelve months of support. The budget period start date has been delayed from 9/1/13 to 9/10/13 due to the National Cancer Institute's (NCI) late receipt of the 30-year Federal Financial Report; however, the expiration date of the budget period remains unchanged (8/31/14). Allowable preaward costs may be charged to this award in accordance with the conditions in the NIH Grants Policy Statement (October 2012) and with institutional requirements for prior approval. The NIH GPS can be found at http://grants.nih.gov/grants/policy/nihgps_2012/index.htm

INFORMATION: In accordance with the National Cancer Institute's (NCI's) Fiscal Year (FY) 2013 funding policies for non-competing (Type 5) awards, this award has been issued at 94% of the

support recommended for this year on last year's Notice of Award. Information on NCI's Funding Policies for FY 2013 is available at: <http://deainfo.nci.nih.gov/grantspolicies/FinalFundLtr.pdf> Information on the NIH Fiscal Policy for FY 2013 grant awards is discussed in the NIH Guide Notice: <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-064.html>

INFORMATION: This award utilizes the unobligated balance from the 30-year Federal Financial Report as an offset in the amount of \$2,728.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Joy Kearse
Email: kearsej@mail.nih.gov **Phone:** 301-631-3002 **Fax:** 301-451-5391

Program Official: Donald G. Blair
Email: db471b@nih.gov **Phone:** 240-276-6190

SPREADSHEET SUMMARY
GRANT NUMBER: 4U01CA033193-32

INSTITUTION: INTERNATIONAL AGENCY FOR RES ON CANCER

<i>Budget</i>	<i>Year 32</i>	<i>Year 33</i>
Salaries and Wages	\$369,270	(b)(5)
Fringe Benefits	\$123,092	(b)(5)
Consultant Services	\$39,566	(b)(5)
Travel Costs	\$2,134	(b)(5)
Other Costs	\$140,860	(b)(5)
TOTAL FEDERAL DC	\$674,922	(b)(5)
TOTAL FEDERAL F&A	\$108,662	(b)(5)
TOTAL COST	\$780,856	(b)(5)

<i>Facilities and Administrative Costs</i>	<i>Year 32</i>	<i>Year 33</i>
F&A Cost Rate 1	16.1%	(b)(5)
F&A Cost Base 1	\$674,922	(b)(5)
F&A Costs 1	\$108,662	(b)(5)

Progress Report Scanning Cover Sheet

5U01CA033193-32

PI Name: **STRAIF, KURT**
Org: **INTERNATIONAL AGENCY FOR RES ON
CANCER**
Start Date: **09/01/2013**
Snap: **N/A (NEEDS TO BE BOOKMARKED)**
Appl ID: **8549689**
Rec'd
Date: **07/08/2013**

Department of Health and Human Services
Public Health Services

Review Group ZCA1RPRB7J1	Type 5	Activity U01	Grant Number 5U01CA033193-34 32
-----------------------------	-----------	-----------------	---

Grant Progress Report

Total Project Period	
From: 09/01/1985	Through: 08/31/2015
Requested Budget Period	
From: 09/01/2013	Through: 08/31/2014

1. TITLE OF PROJECT
Evaluation of Carcinogenic Risks to Humans

2a. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR
(Name and address, street, city, state, zip code)
**Kurt Straif
IARC Monographs Section
International Agency for Research on Cancer
150, Cours Albert Thomas
F-69372 Lyon cedex 08, France**

2b. E-MAIL ADDRESS
imo@iarc.fr

2c. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT
IARC Monographs Section

2d. MAJOR SUBDIVISION
IARC Monographs Section

2e. Tel: **33-4-72.73.85.07** Fax: **33-4-72.73.83.19**

3a. APPLICANT ORGANIZATION
(Name and address, street, city, state, zip code)
**International Agency for Research on Cancer
150, Cours Albert Thomas
F-69372 Lyon cedex 08, France**

3b. Tel: **33-4-72.73.84.85** Fax: **33-4-72.73.85.75**

3c. DUNS: **279551881**

4. ENTITY IDENTIFICATION NUMBER
1900210016A1

6. HUMAN SUBJECTS No Yes

6a. Research Exempt No Yes

If Exempt ("Yes" in 6a):
Exemption No.

If Not Exempt ("No" in 6a):
IRB approval date

5. NAME, TITLE AND ADDRESS OF ADMINISTRATIVE OFFICIAL
Olaf Kelm, External Relations Officer, International Agency for Research on Cancer, 150 Cours Albert Thomas, F-69372 Lyon cedex 08, France

Tel: **33-4-72.73.84.94** Fax: **33-4-72.73.85.64**

E-MAIL: **igo@iarc.fr**

6b. Federal Wide Assurance No. **00005058**

6c. NIH-Defined Phase III Clinical Trial No Yes

7. VERTEBRATE ANIMALS No Yes

7a. If "Yes," IACUC approval Date

7b. Animal Welfare Assurance No.

10. PROJECT/PERFORMANCE SITE(S)

Organizational Name: **Applicant**

DUNS:

8. COSTS REQUESTED FOR NEXT BUDGET PERIOD

8a. DIRECT **\$718,002** 8b. TOTAL **\$833,600**

Street 1:

Street 2:

9. INVENTIONS AND PATENTS No Yes

If "Yes, Previously Reported Not Previously Reported

City: County:

State: Province:

Country: Zip/Postal Code:

Congressional Districts:

11. NAME AND TITLE OF OFFICIAL SIGNING FOR APPLICANT ORGANIZATION (Item 13)
Dr Christopher P. Wild, Director

TEL: **33-4-72.73.85.77** FAX: **33-4-72.73.85.64** E-MAIL: **director@iarc.fr**

12. Corrections to Page 1 Face Page

13. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.	SIGNATURE OF OFFICIAL NAMED IN 11. (In ink) 	DATE 27 June 2013
--	--	-----------------------------

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

DETAILED BUDGET FOR NEXT BUDGET PERIOD – DIRECT COSTS ONLY	FROM 09/01/2013	THROUGH 08/31/2014	GRANT NUMBER 5U01CA033193-31
---	---------------------------	------------------------------	--

List PERSONNEL (*Applicant organization only*)
 Use Cal, Acad, or Summer to Enter Months Devoted to Project
 Enter Dollar Amounts Requested (*omit cents*) for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summer Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
STRAIF, K.	PD/PI	(b)(4), (b)(6)			0	0	0
EL-GHISSASSI, F.	Scientist				83,546	27,849	111,395
BENBRAHIM-TALLAA, L.	Scientist				92,477	30,825	123,302
BOUVARD, V.	Scientist				95,581	31,860	127,441
MATTOCK, H	Editor				74,423	24,808	99,231
EGRAZ, S.	Archivist				47,064	15,688	62,752
RUSSELL, D. * (see note 1 on page 3)	Typist				23,942	7,980	31,922
SUBTOTALS					417,033	139,010	556,043

CONSULTANT COSTS		
EQUIPMENT (<i>Itemize</i>)		
SUPPLIES (<i>Itemize by category</i>)		
TRAVEL One trip of PI to USA for a scientific meeting and to consult with NCI program officials		2,100
INPATIENT CARE COSTS		
OUTPATIENT CARE COSTS		
ALTERATIONS AND RENOVATIONS (<i>Itemize by category</i>)		
OTHER EXPENSES (<i>Itemize by category</i>) See page 3		159,860
SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD		\$ 718,003
CONSORTIUM/CONTRACTUAL COSTS	DIRECT COSTS	
CONSORTIUM/CONTRACTUAL COSTS	FACILITIES AND ADMINISTRATIVE COSTS	
TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (<i>Item 8a, Face Page</i>)		\$ 718,003

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

BUDGET JUSTIFICATION

GRANT NUMBER
5U01CA033193-31

Provide a detailed budget justification for those line items and amounts that represent a significant change from that previously recommended. Use continuation pages if necessary.

OTHER:

- Monograph Working Group Volume 109 (Oct-13)	\$ 69,428
- Monograph Working Group Volume 110 (Jun-14)	\$ 69,428
- Printing of Monographs Volume (\$20,000 X 1)	\$ 20,000
- Books, journals and reproduction costs	\$ 1,004

	\$159,860

Note 1 to detailed budget: only (b) (4) % of D. Russell's salary is anticipated to be charged to the grant.

(b)
(4)
(b)

CURRENT BUDGET PERIOD

FROM
09/01/2012

THROUGH
08/31/2013

Explain any estimated unobligated balance (including prior year carryover) that is greater than 25% of the current year's total budget.

	Total estimated expenditure	Estimated unobligated balance
	-----	-----
DIRECT COSTS	\$718,003	\$0
INDIRECT COSTS	\$115,598	\$0
	-----	-----
TOTAL COSTS	\$833,601	\$0

Program Director/Principal Investigator: STRAIF, Kurt
(Last, first, middle)

**For New and Renewal Applications (PHS 398) – DO NOT SUBMIT UNLESS REQUESTED
For Non-competing Progress Reports (PHS 2590) – Submit only Active Support for Key Personnel**

PHS 398/2590 OTHER SUPPORT

Provide active support for all key personnel. **Other Support includes all financial resources, whether Federal, non-Federal, commercial or institutional, available in direct support of an individual's research endeavors, including but not limited to research grants, cooperative agreements, contracts, and/or institutional awards.** Training awards, prizes, or gifts do not need to be included.

There is no "form page" for other support. Information on other support should be provided in the *format* shown below, using continuation pages as necessary. **Include the principal investigator's name at the top and number consecutively with the rest of the application.** The sample below is intended to provide guidance regarding the type and extent of information requested.

For instructions and information pertaining to the use of and policy for other support, see Other Support in the PHS 398 Part III, Policies, Assurances, Definitions, and Other Information.

Note effort devoted to projects must now be measured using person months. Indicate calendar, academic, and/or summer months associated with each project.

Format

NAME OF INDIVIDUAL

ACTIVE/PENDING

Project Number (Principal Investigator) Source Title of Project (or Subproject)	Dates of Approved/Proposed Project Annual Direct Costs	Person Months (Cal/Academic/ Summer)
The major goals of this project are...		

OVERLAP (summarized for each individual)

LAUBY-SECRETAN, B.

ACTIVE

(b)(4), (b)(6) (Lauby-Secretan)

1/1/2012 – 12/31/2012 (b)(4), calendar

(b)(4), (b)(6)

53,100 euros D.C. (\$67,816)(b)

IARC Monographs Programme 2012

The major goals of this project are to support, in part, a third volume of IARC Monographs each year.

PENDING

(b)(4), (b)(6)

OVERLAP

None.

STRAIF, K.

LOOMIS, D.

BAAN, R.

BENBRAHIM-TALLAA, L.

BOUVARD, V.

EL-GHISSASSI, F.

GROSSE, Y.

GUHA, N.

MATTOCK, H.

There are no other active or pending sources of support for the key scientists on the IARC Monographs project.

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

PROGRESS REPORT SUMMARY	GRANT NUMBER 5U01CA033193-31	
	PERIOD COVERED BY THIS REPORT	
PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR STRAIF, Kurt	FROM 1 September 2012	THROUGH 31 August 2013

APPLICANT ORGANIZATION
International Agency for Research on Cancer

TITLE OF PROJECT (Repeat title shown in Item 1 on first page)
Evaluation of Carcinogenic Risks to Humans

A. Human Subjects (Complete Item 6 on the Face Page)		
Involvement of Human Subjects	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
B. Vertebrate Animals (Complete Item 7 on the Face Page)		
Use of Vertebrate Animals	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
C. Select Agent Research	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
D. Multiple PD/PI Leadership Plan	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
E. Human Embryonic Stem Cell Line(s) Used	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change

SEE PHS 2590 INSTRUCTIONS.

WOMEN AND MINORITY INCLUSION: See PHS 398 Instructions. Use Inclusion Enrollment Report Format Page and, if necessary, Targeted/Planned Enrollment Format Page.

A. Specific Aims

The aim of the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans is to critically review and evaluate the published scientific evidence on carcinogenic hazards to which humans are exposed. These include chemicals, complex mixtures, physical agents, biological agents, occupational exposures, and lifestyle factors. International, interdisciplinary Working Groups (WG) of expert scientists develop the critical reviews and evaluations, which are published in the IARC Monographs series.

B. Studies and Results

IARC convened three Monograph meetings to develop Vol. 106-108 and one workshop as a follow-up of Volume 100. Volumes 100A-F have been published and Vol. 101-103 have been published on-line.

Volume 106: Trichloroethylene, some other chlorinated solvents, and their metabolites, 2-9 Oct. 2012
In October 2012, a WG reviewed the carcinogenicity of several chlorinated solvents (trichloroethylene, tetrachloroethylene, 1,1,1,2-tetrachloroethane, and 1,1,2,2-tetrachloroethane) and some of their metabolites (dichloroacetic acid, trichloroacetic acid, chloral hydrate). Trichloroethylene was classified as carcinogenic to humans (Group 1), based on sufficient evidence for an increased risk of kidney cancer; there was also limited evidence for an association with liver cancer and non-Hodgkin lymphoma (NHL). Tetrachloroethylene was classified as probably carcinogenic to humans (Group 2A) based on limited epidemiological evidence for an increased risk of bladder cancer. Evidence for the carcinogenicity of chloral hydrate was inadequate in epidemiological studies but sufficient in experimental animals. Chloral hydrate was upgraded to Group 2A, on the basis of strong evidence of its genotoxicity in most experimental systems and exposed humans. Multiple chronic bioassays in mice demonstrated that dichloroacetic acid, trichloroacetic acid, 1,1,1,2-tetrachloroethane, or 1,1,2,2-tetrachloroethane increased the incidence of hepatocellular tumours as well as tumors in other organs. These agents were classified as possibly carcinogenic to humans (Group 2B) based on sufficient evidence for carcinogenicity in experimental animals.

Volume 107: Polychlorinated and polybrominated biphenyls, 12-19 February 2013

A total of 209 possible PCB and PBB congeners have been defined, which differ in the number and position of the chlorines and bromines, respectively. PCBs have been widely used in electrical equipment, while PBBs were used primarily as flame retardants; numerous studies have reported exposure of workers in many different settings. Due to their widespread use and their chemical stability, PCBs have become ubiquitous as environmental contaminants. On the basis of sufficient evidence in humans that PCBs cause skin cancer and sufficient evidence in experimental animals, the WG classified PCBs as carcinogenic to humans (Group 1). PCBs with a Toxic Equivalent Factor as defined by the WHO, and which are commonly referred to as "dioxin-like PCBs", were also classified in Group 1 on the basis of extensive evidence of an AhR-mediated mechanism of carcinogenesis that is identical to that of 2,3,7,8-tetrachlorodibenzopara-dioxin (TCDD), and sufficient evidence of carcinogenicity in experimental animals. The carcinogenicity of PCBs overall cannot be solely attributed to the carcinogenicity of the dioxin-like PCBs. On the basis of similarities with PCBs in terms of structure and biological activity, and together with inadequate evidence for carcinogenicity in humans and sufficient evidence in experimental animals, PBBs were upgraded to Group 2A, probably carcinogenic to humans.

Second Workshop on Volume 100: Tumour concordance and mechanisms of carcinogenesis: lessons learned from Volume 100 of the IARC Monographs, 28-30 November 2012

As a follow-up to Volume 100, two Workshops were organized on "Tumour concordance between humans and experimental animals" and "Mechanisms involved in human carcinogenesis". The database capturing animal cancer data and their concordance (or discordance) with human cancers has been finalized, and is now subject to bio-statistical analysis. The second Workshop re-defined and fine-tuned the outline for the database on mechanisms, which will be completed soon. The proposed contents of the forthcoming IARC Scientific Publication, with assigned chapters on 'concordance' and 'mechanisms', was also discussed. The bio-statistical analyses of both databases will be part of this publication.

Volume 108: Some drugs and herbal medicines, 4-11 June 2013

In June 2013, a WG reviewed the carcinogenicity of fourteen drugs and herbal medicines. The drug pioglitazone was classified as probably carcinogenic to humans (Group 2A), based on limited evidence in humans that pioglitazone use is associated with urinary bladder cancer and sufficient evidence in experimental animals. The drugs digoxin and hydrochlorothiazide were classified as possibly carcinogenic to humans (Group 2B), based on limited evidence in humans that digoxin use is associated with breast cancer and that hydrochlorothiazide use is associated with squamous cell carcinoma of the skin and lip. The drugs primidone, sulfasalazine, pentosan polysulfate sodium, triamterene, and the herbal medicines - or their components - whole leaf extract of Aloe Vera, goldenseal root powder, *Ginkgo biloba* leaf extract, Kava extract, and pulegone, were classified as Group 2B, based on sufficient evidence in experimental animals. The drugs rosiglitazone and methylene blue were evaluated as not classifiable as to their carcinogenicity to humans (Group 3).

The full text of all *Monographs* is available free of charge on <http://monographs.iarc.fr/>. All volumes published since Vol. 43 (1989) and Supplements 1, 4 and 7 are now available, as well as the summary sections of Vol. 1-42. The Lancet Oncology summaries are also freely available via the Lancet Oncology website.

D. Plans. During the next budget period, IARC will convene two Monograph Working Groups and two Advisory Groups:

Vol. 109: Ambient Air Pollution, 8-15 Oct. 2013

Advisory Group to Recommend on Quantitative Risk Characterization for the IARC Monogr., 18-19 Nov. 2013

Advisory Group to Recommend on Priorities for the IARC Monographs during 205-2019, 7-9 April 2014

Vol. 110: Agents to be announced soon at <http://monographs.iarc.fr/ENG/Meetings/index.php>, 3-10 June 2014

IARC will also focus attention on checking Vol. 104-109 and preparing them for publication and will continue making the full text of all Monographs freely available. Further dissemination improvements will include: a) completion of a fully searchable relational database of Monograph results, enabling complex queries, and linking to other IARC databases (IARC Blue Books, Globocan, etc); b) development of ePub format of Monographs for delivery to e-book readers and tablets.

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100A, A Review of Human Carcinogens: Pharmaceuticals. IARC, Lyon. Also published on-line (available free of charge): <http://monographs.iarc.fr/ENG/Monographs/vol100A/index.php>

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100B, A Review of Human Carcinogens: Biological Agents. IARC, Lyon. Also published on-line (available free of charge): <http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php>

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100C, A Review of Human Carcinogens: Arsenic, Metals, Fibres, and Dusts. IARC, Lyon. Also published on-line (available free of charge): <http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php>

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100D, A Review of Human Carcinogens: Radiation. IARC, Lyon. Also published on-line (available free of charge): <http://monographs.iarc.fr/ENG/Monographs/vol100D/index.php>

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100E, A Review of Human Carcinogens: Personal Habits and Indoor Combustions. IARC, Lyon. Also published on-line (available free of charge): <http://monographs.iarc.fr/ENG/Monographs/vol100E/index.php>

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100F, A Review of Human Carcinogens: Chemical Agents and Related Occupations. IARC, Lyon. Also published on-line (available free of charge): <http://monographs.iarc.fr/ENG/Monographs/vol100F/index.php>

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 102, Non-Ionizing Radiation, Part 2: Radiofrequency Electromagnetic Fields. IARC, Lyon. Published on-line (available free of charge): <http://monographs.iarc.fr/ENG/Monographs/vol102/index.php>

IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 103, Bitumen and bitumen fumes, and some heterocyclic polycyclic aromatic hydrocarbons. IARC, Lyon. Published on-line (available free of charge): <http://monographs.iarc.fr/ENG/Monographs/vol103/index.php>

Grosse Y, Loomis D, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K; International Agency for Research on Cancer Monograph Working Group. International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of some drugs and herbal medicines. (submitted to Lancet Oncol. – will be immediately available free of charge on the Lancet Oncology website)

Guha N, Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Baan R, Mattock H, Straif K; International Agency for Research on Cancer Monograph Working Group. Lancet Oncol 2012 Dec;13(12):1192-3. PMID:23323277 (available free of charge: [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(12\)70485-0/fulltext#article_upsell](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70485-0/fulltext#article_upsell))

Lauby-Secretan B, Loomis D, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K; International Agency for Research on Cancer Monograph Working Group. Lancet Oncol 2013 Apr;14(4):287-8. PMID:23499544 (available free of charge: [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(13\)70104-9/fulltext#article_upsell](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70104-9/fulltext#article_upsell))

Straif K, Stayner L, Demers PA, Landrigan PJ. Use of meta-analyses by IARC Working Groups. Environ Health Perspect. 2012 Sep;120(9):A342-3. PMID:23487835, Free PMC Article

Program Director/Principal Investigator (Last, first, middle): STRAIF, Kurt

GRANT NUMBER
5U01CA033193-31

CHECKLIST

1. PROGRAM INCOME (See instructions.)

All applications must indicate whether program income is anticipated during the period(s) for which grant support is requested. If program income is anticipated, use the format below to reflect the amount and source(s).

Budget Period	Anticipated Amount	Source(s)

2. ASSURANCES/CERTIFICATIONS (See instructions.)

In signing the application Face Page, the authorized organizational representative agrees to comply with the policies, assurances and/or certifications listed in the application instructions when applicable. Descriptions of individual assurances/certifications are provided in Part III of the PHS 398, and listed in Part I, 4.1 under Item 14. If unable to certify compliance, where applicable, provide an explanation and place it after the Progress Report (Form Page 5).

3. FACILITIES AND ADMINISTRATIVE (F&A) COSTS

Indicate the applicant organization's most recent F&A cost rate established with the appropriate DHHS Regional Office, or, in the case of for-profit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office.

F&A costs will **not** be paid on construction grants, grants to Federal organizations, grants to individuals, and conference grants. Follow any additional instructions provided for Research Career Awards, Institutional National Research Service Awards, Small Business Innovation Research/Small Business Technology Transfer Grants, foreign grants, and specialized grant applications.

DHHS Agreement dated: 08/11/2010 No Facilities and Administrative Costs Requested.

No DHHS Agreement, but rate established with _____ Date _____

CALCULATION*

Entire proposed budget period: Amount of base \$ 718,003 x Rate applied 16.10 % = F&A costs \$ 115,598

Add to total direct costs from Form Page 2 and enter new total on Face Page, Item 8b.

*Check appropriate box(es):

Salary and wages base Modified total direct cost base Other base (Explain)

Off-site, other special rate, or more than one rate involved (Explain)

Explanation (Attach separate sheet, if necessary.):

Base is total direct costs.

ALL PERSONNEL REPORT

GRANT NUMBER
5U01CA033193-31

Place this form at the end of the signed original copy of the application. Do not duplicate.

Always list the PD/PI(s). In addition, list all other personnel who participated in the project during the current budget period for at least one person month or more, regardless of the source of compensation (a person month equals approximately 160 hours or 8.3% of annualized effort). Use the following abbreviated categories for describing Role on Project:

- PD/PI
- Co-Investigator
- Faculty
- Postdoctoral (scholar, fellow, or other postdoctoral position)
- Technician
- Staff Scientist (doctoral level)
- Statistician
- Graduate Student (research assistant)
- Non-student Research Assistant
- Undergraduate Student
- High School Student
- Consultant
- Other (please specify)

If personnel are supported by a Reentry or Diversity Supplement please indicate such after the Role on Project, using the following abbreviations: RS - Reentry Supplement; DS - Diversity Supplement.

Use Cal (calendar), Acad, or Summer to enter months devoted to project.

Commons ID	Name	Degree(s)	SSN (last 4 digits)	Role on Project	DoB (MM /YY)	Cal	Acad	Summer
k.straif	Straif, Kurt	MD, PhD	n/a	Principal Investig.	(b)(6)	(b)(4), (b)(6)		
DLOOMIS	Loomis, Dana	PhD	(b)	Co-Investigator				
	Baan, Robert	PhD	n/a	Scientist				
	Benbrahim-Tallaa, Lamia	PhD	(b)	Staff Scientist				
	Bouvard, Véronique	PhD	n/a	Staff Scientist				
	Egraz, Sandrine	BA	n/a	Other (Archivist)				
	Elbers, Elisabeth	MA	n/a	Technician				
	El-Ghissassi, Fatiha	PhD	n/a	Staff Scientist				
	Grosse, Yann	PhD	n/a	Staff Scientist				
	Guha, Neela	PhD	(b)	Staff Scientist				
	Kajo, Brigitte	n/a	n/a	Other (Archivist)				
	Lauby-Secretan, Béatrice	PhD	n/a	Staff Scientist				
	Leroux, Annick	BA	n/a	Technician				
	Lorenzen-Augros, Helene	B/A	n/a	Other (Secretary)				

ALL PERSONNEL REPORT

GRANT NUMBER
5U01CA033193-31

Place this form at the end of the signed original copy of the application. Do not duplicate.

Always list the PD/PI(s). In addition, list all other personnel who participated in the project during the current budget period for at least one person month or more, regardless of the source of compensation (a person month equals approximately 160 hours or 8.3% of annualized effort). Use the following abbreviated categories for describing Role on Project:

- PD/PI
- Co-Investigator
- Faculty
- Postdoctoral (scholar, fellow, or other postdoctoral position)
- Technician
- Staff Scientist (doctoral level)
- Statistician
- Graduate Student (research assistant)
- Non-student Research Assistant
- Undergraduate Student
- High School Student
- Consultant
- Other (please specify)

If personnel are supported by a Reentry or Diversity Supplement please indicate such after the Role on Project, using the following abbreviations: RS - Reentry Supplement; DS - Diversity Supplement.

Use Cal (calendar), Acad, or Summer to enter months devoted to project.

Commons ID	Name	Degree(s)	SSN (last 4 digits)	Role on Project	DoB (MM /YY)	Cal	Acad	Summer
	Mattock, Heidi	PhD	n/a	Other (Editor)	(b)(6)	(b)(4), (b)(6)		
	Russell, Dorothy	BA	n/a	Other (Typist)				

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Dana Loomis		POSITION TITLE Professor	
eRA COMMONS USER NAME (credential, e.g., agency login) (b) (4)			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Oberlin College, Oberlin OH, USA	BA	1978	Geology
University of North Carolina, Chapel Hill, USA	MSPH	1986	Environ. Sciences
University of North Carolina, Chapel Hill, USA	PhD	1989	Epidemiology

A. Personal statement

I am a senior investigator with research interests in occupational and environmental epidemiology and exposure assessment. My research is directed toward the role of environmental and occupational exposures in carcinogenesis. Ongoing projects are investigating the role of asbestos fiber size and shape in determining cancer risk and development of methods for occupational cancer studies. Related previous work includes research on cancer risks from occupational exposure to polychlorinated biphenyls and electromagnetic fields and ethnic disparities in occupational cancer risks. I have extensive experience as Principal Investigator and Co-Investigator in large, complex research projects and have the scientific and managerial skills required to bring such projects to successful completion.

B. Positions and Honors

Employment

1989-96 Assistant Professor, Department of Epidemiology, University of North Carolina, Chapel Hill, NC
 1995 Visiting Scientist, Department of Air Quality, Wageningen University, The Netherlands
 1996-2001 Associate Professor, Department of Epidemiology, University of North Carolina, Chapel Hill, NC
 1997 Fulbright Scholar, Instituto Nacional de Salud Pública de México, Cuernavaca, Mexico
 2001-2006 Professor, Department of Epidemiology, University of North Carolina, Chapel Hill, NC
 2002-2006 Professor, Department of Environmental Sciences & Engineering, University of North Carolina
 2006 Interim Chair, Department of Epidemiology, University of North Carolina, Chapel Hill, NC
 2007-2010 Professor of Environmental & Occupational Health, University of Nevada, Reno NV
 2008-2010 Director, School of Public Health, University of Nevada, Reno NV
 2010-2012 Professor and Chair, Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha NE
 2010-2012 Associate Director, Cancer Prevention & Control, Eppley Cancer Center, University of Nebraska Medical Center, Omaha NE
 2012- Deputy Head, Section of IARC Monographs, International Agency for Research on Cancer, Lyon, France

Editorial, Professional Societies and Advisory Boards (selected)

1998-2003 Member & Chair, Safety & Occupational Health Study Section, Center for Scientific Review, DHHS
 2006- Chair, Scientific Committee on Epidemiology, International Commission on Occupational Health
 2009- Editor, *Occupational & Environmental Medicine*
 2010-2012 Member, National Toxicology Program, Board of Scientific Counselors

C. Selected peer-reviewed publications

- Loomis DP, Savitz DA, Ananth CV. Breast cancer mortality among female electrical workers in the United States. *JNCI* 1994;86:921-925.
- Savitz DA, Loomis DP. Magnetic field exposure in relation to leukemia and brain cancer mortality among electric utility workers. *Am J Epidemiol* 1995;141:123-134.
- Loomis DP, Wolf SH. Mortality of workers at the Y-12 nuclear materials plant, 1947-1990. *Am J Ind Med* 1996;29:131-141.
- Loomis DP, Browning SH, Schenck AP, Gregory E, Savitz DA. Cancer mortality among electric utility workers exposed to polychlorinated biphenyls. *Occupational and Environmental Medicine* 1997;54:720-728.
- Loomis D, Castillejos M, Gold DM, McDonnell W, Borja-Aburto VH. Air pollution and infant mortality in Mexico City. *Epidemiology* 1999;10:118-123.
- Loomis D, Schulz M. Mortality from six work-related cancers among African-Americans and Latinos. *Am J Ind Med* 2000;38:565-575.
- Loomis D, Wolf S, Runyan DW, Marshall SW, Berry JD. Homicide on the job: workplace and community determinants. *Am J Epidemiol* 2001;154:410-417.
- Loomis D, Marshall SW, Wolf SH, Runyan CW, Butts JD. Effectiveness of safety measures recommended for prevention of workplace homicide. *JAMA* 2002;287:1011-1017.
- Kato M, Loomis D, Brooks LM, Gattas GFJ, Gomes L, Carvalho AB, Rego MAV, DeMarini DM. Urinary biomarkers in charcoal workers exposed to wood smoke in Bahia, Brazil. *Cancer Epidemiol Biomarkers Prev* 2004;13:1005-12.
- Caceres DD, Pino P, Montesinos N, Atalah E, Amigo H, Loomis D. Exposure to inorganic arsenic in drinking water and total urinary arsenic concentration in a Chilean population. *Environ Res* 2005;98:151-159.
- Rojas-Martinez R,* Pérez-Padilla R, Olaiz-Fernandez G, Mendoza-Alvarado L, Moreno-Macías H, Fortoul T, McDonnell W, Loomis D, Romieu I. Lung Function Growth in Children with Long-Term Exposure to Air Pollutants in Mexico City. *Am J Respir Crit Care Med*. 2007;176:377-84.
- Brown JM, Sobsey MD, Loomis D. Point-of-use drinking water treatment in Cambodia: a randomized, controlled trial of locally made ceramic filters. *Am J Trop Med Hyg* 2008;79:394-400.
- Loomis D, Schulman MD, Bailer AJ, Stainback K, Wheeler M, Richardson DB, Marshall SW. Political Economy of US States and Rates of Fatal Occupational Injury. *Am J Public Health* 2009;99:1400-8.
- Loomis D, Dement JM, Wolf SH, Richardson DB. Lung cancer mortality and fiber exposure among North Carolina asbestos textile workers. *Occup Environ Med* 2009;66:535-42.
- Loomis D, Dement JM, Richardson DB, Wolf S. Asbestos fiber dimensions and lung cancer mortality among workers exposed to chrysotile. *Occupational & Environmental Medicine* 2010;67:580-4. PMID 19897464.
- Del Razo LM, Garcia-Vargas GG, Valenzuela OL, Hernández Castellanos E, Sánchez-Peña LC, Drobná Z, Loomis D, Styblo M. Exposure to arsenic in drinking water is associated with increased prevalence of diabetes: a cross-sectional study in the Zimapan and Lagunera Regions in Mexico. *Environmental Health* 2011;10:73.
- Loomis D, Dement JM, Elliott L, Richardson DB, Kuempel E, Stayner LT. Increased lung cancer mortality among chrysotile asbestos textile workers is more strongly associated with exposure to long, thin fibers. *Occup Environ Med* 2012 doi:10.1136/oemed-2012-100676.

D. Research Support

CURRENT

R01 ES015326-01A1 Environmental Arsenic and Diabetes Mellitus

Project Role: Principal Investigator, UNR

Subcontract to University of North Carolina, M. Styblo, PI

Agency: NIEHS Period: 8/07/08-5/31/13

This is a translational research project that examines the association between environmental exposures to arsenic and diabetes mellitus, focusing on arsenic metabolism as a key determinant of the outcome of exposure. Cell culture, animal and human population studies are included in this project.

COMPLETED

R01 CA117841 Cohort analysis methods for occupational cancer studies

Project Role: Principal Investigator, UNR

Subcontract to the University of North Carolina, D. Richardson, PI

Agency: NCI

This competing renewal of a current R01 project continues development of analytical methods for occupational cohort studies.

Overlap: None

1 U54 OH 010162 – 01 Central States Center for Agricultural Safety and Health

Project Role: Deputy Director & Project Leader

Agency: NIOSH Period: 10/01/2011-9/29/2016

This grant establishes the Central States Center for Agricultural Safety and Health, a multi-disciplinary research center focusing primarily on respiratory disease research, injury prevention, and educational needs of farmers and ranchers.

Overlap: None

R01 2 OH007803 Chrysotile and lung cancer: time-related effects and pooled analyses

Project Role: Principal Investigator

Agency: NIOSH Period: 8/01/08-1/31/11

This application continues and expands the North Carolina Asbestos Textile Study with the use of advanced statistical methods and mechanistic models to examine time-related effects of exposure on lung cancer risk. Pooled analyses of North Carolina and South Carolina asbestos textile worker cohorts will also be conducted to assess exposure-response relationships with enhanced precision.

R01 OH007803 Chrysotile: New Exposure Indices and Cancer Epidemiology

Project Role: Principal Investigator

Agency: NIOSH Period: 09/30/03–09/29/08

This historical cohort study of asbestos textile workers seeks to assess new measures of exposure to chrysotile asbestos and quantify exposure-response relationships for lung cancer.

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Mattock, Heidi Karen		POSITION TITLE Scientific editor	
eRA COMMONS USER NAME (credential, e.g., agency login) (b) (4)			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of Sussex, Lewes, England University of Dundee, Dundee, Scotland	BSc PhD	06/94 11/99	Biology with European Studies (French) Biochemistry/Cell Biology

A. Personal Statement

With a PhD in cancer research, I have had 13 years experience as a scientific and technical editor, both in-house and freelance, working mainly for the World Health Organization (WHO). I have been responsible for editing the *WHO Classification of Tumours* ("Blue Books") and the Joint FAO/WHO Expert Committee on Food Additives and Joint Meeting on Pesticide Residues (JECFA/JMPR) monographs, as well as numerous technical books, reports and journal articles on diverse topics related to health, medicine and development.

B. Positions

- 2012- *Scientific editor, IARC Monographs, IARC, Lyon, France*
- 2009-2012 *Scientific editor for the World Health Organization Classification of Tumours series (pathology and genetics of tumours), Section of Molecular Pathology, IARC, Lyon, France*
- 2003-2009 *Freelance scientific and technical editor*
Departments within WHO: Special Programme for Research and Training in Tropical Diseases, International Programme on Chemical Safety, HIV/AIDS, Essential Drugs and Medicines Policy, Global Programme on Evidence for Health Policy, *WHO Bulletin*.
Editor for Joint FAO/WHO Expert Committee on Food Additives and Joint Meeting on Pesticide Residues (JECFA/JMPR), Geneva and Rome, 2003-2009: editing of technical reports and toxicological monographs.
Other clients: Sanofi-Pasteur MSD, DodetBiosciences, The Academy of Sciences for the Developing World
- 2000-2002 *Scientific editor for World Cancer Report (a 350-page book directed to a multidisciplinary professional readership and based on a comprehensive appraisal of all aspects of cancer), Office of the Director, IARC, Lyon, France*
- 1998-1999 *Research assistant, CRC Cell Transformation Laboratories, Department of Biochemistry, Medical Sciences Institute, University of Dundee, Scotland*

C. Selected Peer-reviewed Publications

- Lauby-Secretan B, Loomis D, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K; International Agency for Research on Cancer Monograph Working Group (2013). Carcinogenicity of polychlorinated biphenyls and polybrominated biphenyls. *Lancet Oncol.*, 14:287–288.
- Guha N, Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Baan R, Mattock H, Straif K; International Agency for Research on Cancer Monograph Working Group (2012). Carcinogenicity of

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolites. *Lancet Oncol.*, 13:1192–1193.

Mattock H (2002) Brought to book: first steps in publishing. *Science's Next Wave*. Internet article: <http://intl-nextwave.sciencemag.org/cgi/content/full/2002/01/30/3>

Mattock H, Lane DP, Warbrick E (2001). Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP-miniprotein. *Exp. Cell Res.*, 265:234–241.

Mattock H, Jares P, Zheleva DI, Lane DP, Warbrick E, Blow JJ (2001). Use of peptides from p21(Waf1/Cip1) to investigate PCNA function in *Xenopus* egg extracts. *Exp. Cell Res.*, 265:242–251.

International Agency for Research on Cancer



150 cours Albert Thomas
69372 Lyon cedex 08, France

Section of IARC Monographs
Tel.: +33 4 72 73 85 07
Fax: +33 4 72 73 83 19
E-mail: imo@iarc.fr
<http://monographs.iarc.fr>

Division of Central Grants Processing, OER
National Institutes of Health
6705 Rockledge Drive, MSC 7986,
Suite 5016
Bethesda, MD 20817
USA

Special courier: tel. 1-301-594.6584

Ref.: IMO/43/4

25 June 2013

Grant No 5U01CA033193-31


Dear Sirs,

I enclose our Grant Progress Report for the budget period from 1 September 2012 to 31 August 2013, including the budget request of the next period from 1 September 2013 to 31 August 2014.

Biosketches for two new staff members are included.

I trust the enclosed report is satisfactory and look forward to our continued collaboration.

Yours sincerely,



Kurt Straif, MD, PhD
Head, IARC Monographs Section

ENCL: As mentioned